The clearance marks a significant milestone for Moderna mRNA flu vaccine development, representing the company’s fourth FDA-approved product. Shares in Nasdaq-listed Moderna rose 1.77% to $58 at market open on August 6, compared to a pre-announcement market close of $56.99. The vaccine is licensed for preventing seasonal influenza in adults aged 50 years and older, utilizing the same messenger RNA platform that powered the company’s Covid-19 shots.
Path to mFlusiva FDA Approval
Securing the mFlusiva FDA approval was not a straightforward process. The agency initially issued a rare refuse to file (RTF) letter in February 2026. At the time, the FDA’s Center for Biologics Evaluation and Research then-chief, Vinay Prasad, noted that the Phase III trial failed to use an optimal comparator. The study for adults aged 50 to 64 compared mFlusiva against a standard-dose licensed vaccine rather than a high-dose option typically preferred for older demographics.
News of the FDA declining to even review the application generated shockwaves across the vaccine development sector. Moderna’s stock slumped by more than 10% immediately following the RTF letter. However, a reprieve arrived just a week later when the FDA accepted an amended application after meeting with Moderna executives to discuss the data.
In June, the FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the jab outweighed its risks across both the 50-to-64-year age group and patients aged 65 years and older. The traditional approval for the 50 to 64 cohort was based on a Phase III trial that enrolled more than 40,000 individuals. The data demonstrated that mFlusiva achieved superiority over standard-dose licensed vaccines in preventing influenza-induced illness.
For the older age group, a separate Phase III trial evaluated mFlusiva against a high-dose comparator. Adults aged 65 and older received accelerated approval, a regulatory pathway often used when a drug treats a serious condition. As part of this accelerated approval, Moderna will be required to conduct a postmarketing clinical trial to confirm the clinical benefit in this specific population.
Political Landscape and RFK Jr Vaccine Policy
Despite the clinical success, the Moderna mRNA flu vaccine enters a complex US vaccine landscape marked by intense political scrutiny. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has long claimed that mRNA technology poses a higher risk profile than traditional vaccines, despite clinical evidence to the contrary. Under his leadership, the HHS cancelled $500 million worth of federally funded mRNA contracts in August 2025.
This RFK Jr vaccine policy extends beyond funding cuts and into the structure of federal advisory panels. The health secretary has replaced members of the Advisory Committee on Immunization Practices (ACIP) with individuals known for being critical of vaccines and government guidance issued during the Covid-19 pandemic. In December 2025, the newly configured panel controversially voted to revoke newborn hepatitis B vaccine recommendations, a decision met with dismay from medical bodies and charities.
The shifting composition of the ACIP creates a cloud of uncertainty over newly approved vaccines. Even when the FDA determines a product is safe and effective, the subsequent CDC immunization recommendations dictate whether the vaccine will actually be utilized by healthcare providers and covered by insurance programs.
Market Impact and mRNA Technology Advantages
Analysts view the regulatory win as a positive signal for Moderna’s revenue guidance, especially as the company seeks to diversify its portfolio beyond Covid-19. William Blair analysts project a conservative $1.16 billion peak sales forecast for mFlusiva. This revenue potential relies heavily on the vaccine’s ability to capture market share from established flu shot manufacturers.
A key advantage of mRNA vaccines is the ability to manufacture updated versions in response to emerging flu strains much faster than traditional protein-based vaccines. This manufacturing agility allows companies to respond rapidly if the seasonal flu strains mutate or if a novel pandemic threat emerges. Public health officials view this rapid scalability as a critical tool in the ongoing fight against respiratory viruses.
Influenza remains a leading cause of hospitalization and death among older adults in the United States. The virus mutates rapidly, requiring vaccine manufacturers to update their formulations annually. Traditional egg-based production methods can take up to six months to yield a new vaccine, sometimes resulting in mismatched strains by the time flu season peaks. The mFlusiva FDA approval introduces a platform that can be updated in a matter of weeks, potentially offering a closer match to circulating strains and better protection for vulnerable populations.
What Happens Next
Before the Moderna mRNA flu vaccine can reach the public through national programs, it requires formal CDC immunization recommendations. The CDC must recommend the jab for use in upcoming flu seasons to secure its place in standard medical practice. Consequently, all eyes in the medical and investment communities will be on the next ACIP meeting scheduled for mid-October.
Given the current composition of the advisory panel and the overarching RFK Jr vaccine policy, the upcoming vote remains highly unpredictable. If the committee recommends mFlusiva, it will pave the way for broad insurance coverage and widespread distribution across pharmacies and clinics. If the panel delays or denies the recommendation, Moderna could face significant commercial headwinds despite holding an FDA-approved product. Stakeholders will closely monitor the October meeting for signals about the future integration of mRNA technology in routine preventive care.
— Aisha Mensah, health desk, AXO News